Related Experiment Video
Updated: Feb 15, 2026
Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
Published on: September 11, 2015
Computational Analysis of Epidermal Growth Factor Receptor Mutations Predicts Differential Drug Sensitivity Profiles
Sravani Akula1, Swapna Kamasani1, Sree Kanth Sivan2
1Molecular Medicine and Therapeutics Laboratory, Centre for Plant Molecular Biology, Osmania University, Hyderabad, India.
Introduction:
A significant proportion of patients with lung cancer carry mutations in the EGFR kinase domain. The presence of a deletion mutation in exon 19 or L858R point mutation in the EGFR kinase domain has been shown to cause enhanced efficacy of inhibitor treatment in patients with NSCLC. Several less frequent (uncommon) mutations in the EGFR kinase domain with potential implications in treatment response have also been reported. The role of a limited number of uncommon mutations in drug sensitivity was experimentally verified. However, a huge number of these mutations remain uncharacterized for inhibitor sensitivity or resistance.
Methods:
A large-scale computational analysis of clinically reported 298 point mutants of EGFR kinase domain has been performed, and drug sensitivity profiles for each mutant toward seven kinase inhibitors has been determined by molecular docking. In addition, the relative inhibitor binding affinity toward each drug as compared with that of adenosine triphosphate was calculated for each mutant.
Results:
The inhibitor sensitivity profiles predicted in this study for a set of previously characterized mutants correlated well with the published clinical, experimental, and computational data. Both the single and compound mutations displayed differential inhibitor sensitivity toward first- and next-generation kinase inhibitors.
Conclusions:
The present study provides predicted drug sensitivity profiles for a large panel of uncommon EGFR mutations toward multiple inhibitors, which may help clinicians in deciding mutant-specific treatment strategies.
Insights
This study predicts drug sensitivity for numerous uncommon EGFR mutations in non-small cell lung cancer (NSCLC). These findings aid clinicians in selecting targeted inhibitor treatments for patients with specific EGFR mutations.
Area of Science:
- Oncology
- Computational Biology
- Pharmacology
Background:
- Activating mutations in the Epidermal Growth Factor Receptor (EGFR) kinase domain are common in non-small cell lung cancer (NSCLC).
- Specific mutations like exon 19 deletions or L858R confer sensitivity to EGFR inhibitors.
- Many uncommon EGFR mutations remain uncharacterized regarding their response to kinase inhibitors.
Purpose of the Study:
- To computationally predict drug sensitivity profiles for a comprehensive set of uncommon EGFR kinase domain mutations.
- To evaluate the differential sensitivity of various EGFR mutants to multiple kinase inhibitors.
- To provide data supporting personalized treatment strategies for NSCLC patients with diverse EGFR mutations.
Main Methods:
- A large-scale computational analysis using molecular docking was performed on 298 reported EGFR kinase domain point mutants.
- Drug sensitivity profiles were determined for each mutant against seven kinase inhibitors.
- Relative inhibitor binding affinities were calculated compared to adenosine triphosphate (ATP).
Main Results:
- Predicted inhibitor sensitivity profiles for known mutants showed good correlation with existing clinical and experimental data.
- Both single and compound EGFR mutations exhibited varied sensitivity to first- and next-generation kinase inhibitors.
- Differential drug sensitivity was observed across the tested EGFR mutants and inhibitors.
Conclusions:
- This study presents predicted drug sensitivity profiles for a wide array of uncommon EGFR mutations.
- The findings can assist clinicians in developing mutant-specific treatment strategies for NSCLC.
- Understanding the sensitivity of rare EGFR mutations is crucial for optimizing targeted therapies.
More Related Videos
Related Concept Videos
01:13Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
01:26Receptor Tyrosine Kinases
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
01:39Mutations
00:36Viral Mutations